Pulmagen Therapeutics Limited
Respiratory Pharmaceuticals Company
Contact Name
Dr. Christopher Ashton
Company Position
Chief Executive Officer
Contact Address
Stoke Court
Stoke Poges
Slough
Bucks
SL2 4SY
UK
Latest News
2nd February 2010
Galapagos NV announces the acquisition of Argenta Discovery 2009 Ltd. The combination with Galapagos’ service division BioFocus creates one of the world’s largest drug discovery service organisations
Read this article
More News
26th November 2007
Argenta Discovery and Dr Reddy's Laboratories, announce a major milestone in their development programme to treat chronic respiratory disease.
Read this article
24th October 2007
Argenta has announced that it has extended its integrated contract drug discovery agreement with Genentech, Inc. for a further two years.
Read this article
15th October 2007
Argenta Discovery Limited announces a major milestone in a joint programme with AstraZeneca aimed at identifying improved bronchodilators to treat COPD.
Read this article
Pulmagen Therapeutics was formed was following the acquisition of Argenta Discovery 2009 Limited by Galapagos NV. Ownership of Argenta’s respiratory development programs transferred into Pulmagen Therapeutics, a development stage biotechnology company that aims to progress novel therapies to treat chronic respiratory diseases including COPD, severe asthma and cystic fibrosis. These therapies aim to deliver both improved bronchodilator symptomatic relief and treat the underlying inflammatory disease process. Pulmagen intends to progress its programs through Phase IIa proof of concept clinical trials and identify strategic partners for later stage clinical development. The company has partnered respiratory development programs with AstraZeneca, Domantis (GSK) and Dr. Reddy’s.
Pulmagen’s programmes include:
• ADC4022, a low dose inhaled theophylline/inhaled corticosteroid combination product that is designed to restore steroid responsiveness in COPD and severe asthma and thus to provide an effective anti-inflammatory therapy for these diseases. A 4 week Phase IIa study has generated positive proof of concept data for this approach and 3 month studies to extend these initial promising findings are being planned
• An oral CRTh2 antagonist programme for the treatment of asthma, COPD and allergic diseases. The lead molecule ADC3680B is due to enter Phase I in August 2010 and two back-up molecules are in GLP toxicology studies and will be ready for the start of Phase I in January 2011
• An inhaled PPARc agonist programme for the treatment of COPD, severe asthma and cystic fibrosis. Two candidate compounds are in pre-clinical safety studies with Phase I due to start in H1 2011
